Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies

Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies

Current screening methods for ovarian cancer can only detect advanced disease. Earlier detection has proved difficult because the molecular precursors involved in the natural history of the disease are unknown. To identify early driver mutations in ovarian cancer cells, we used dense whole genome se...

Full description

Bibliographic Details
Main Authors: Karin Hellner, Fabrizio Miranda, Donatien Fotso Chedom, Sandra Herrero-Gonzalez, Daniel M. Hayden, Rick Tearle, Mara Artibani, Mohammad KaramiNejadRanjbar, Ruth Williams, Kezia Gaitskell, Samar Elorbany, Ruoyan Xu, Alex Laios, Petronela Buiga, Karim Ahmed, Sunanda Dhar, Rebecca Yu Zhang, Leticia Campo, Kevin A. Myers, María Lozano, María Ruiz-Miró, Sónia Gatius, Alba Mota, Gema Moreno-Bueno, Xavier Matias-Guiu, Javier Benítez, Lorna Witty, Gil McVean, Simon Leedham, Ian Tomlinson, Radoje Drmanac, Jean-Baptiste Cazier, Robert Klein, Kevin Dunne, Robert C. Bast Jr, Stephen H. Kennedy, Bassim Hassan, Stefano Lise, María José Garcia, Brock A. Peters, Christopher Yau, Tatjana Sauka-Spengler, Ahmed Ashour Ahmed
Format: Article
Language:English
Published: Elsevier 2016-08-01
Series:EBioMedicine
Subjects:
Ovarian cancer
Fallopian tube
BRCA mutations
SOX2
Screening
Precancer
Online Access:http://www.sciencedirect.com/science/article/pii/S235239641630305X

Internet

http://www.sciencedirect.com/science/article/pii/S235239641630305X

Similar Items